Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Q2-25 results (ended 30 Jun 25): Ionis generated $452.0 M revenue, +101% YoY, fuelled by a $280 M upfront from Ono (sapablursen), a $30 M milestone from AstraZeneca and $19.3 M of first-time U.S. TRYNGOLZA sales. Royalty streams (mostly SPINRAZA & WAINUA) added $70.0 M.
Operating expenses rose 7% to $312.2 M as SG&A expanded with launches while R&D fell modestly; operating profit reached $139.8 M versus a $66.1 M loss. Net income swung to $123.6 M ($0.70 diluted EPS) from a $66.3 M loss.
H1-25: Revenue climbed 69% to $583.7 M; net loss narrowed to $23.4 M. Operating cash flow was essentially breakeven ( $0.6 M) versus a $269.8 M outflow a year earlier.
Balance sheet: Cash increased to $297.3 M; cash + short-term investments totalled ~$2.29 B. Shareholders’ equity improved to $631.7 M. Current liabilities grew to $897.2 M after the 0% convertible notes ($630.1 M) moved current; total liabilities stand at $2.35 B.
Strategic updates: 1) Ono deal brings up to $940 M future milestones; 2) AstraZeneca advanced opemalirsen into Phase 2b; 3) first independent commercial launch with FDA-approved TRYNGOLZA for FCS. Company maintains single-segment reporting and full valuation allowance on deferred tax assets.